NeuroSense Therapeuticsの空売り状況は、投資家がNeuroSense Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

NeuroSense Therapeutics (NASDAQ:NRSN) 株価情報, 空売り情報

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics Ltd

Piper Sandler analyst Mark Lear maintains Prairie Operating (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) with a Overweight and lowers the price target from $11 to $10.

News

Price Target

Analyst Ratings

PROP

Piper Sandler Maintains Overweight on Prairie Operating, Lowers Price Target to $10

UBS analyst Jon Windham maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Neutral and raises the price target from $4.5 to $6.

FLNC

UBS Maintains Neutral on Fluence Energy, Raises Price Target to $6

Piper Sandler analyst Mark Lear maintains Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) with a Overweight and lowers the price target from $20 to $19.

Piper Sandler Maintains Overweight on Permian Resources, Lowers Price Target to $19

Macro Economic Events

WIIM

Economics

Major indexes are higher following softer-than-expected April inflation readings. Additionally, investors continue to weigh US-China trade progress and President Trump's Middle East trip.

SPDR Dow Jones Industrial Average ETF Trust

The Dow is lower amid weakness in one of its largest components, UnitedHealth, which fell after announcing a CEO change and suspending guidance.

Piper Sandler analyst Mark Lear maintains Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) with a Neutral and lowers the price target from $34 to $30.

Piper Sandler Maintains Neutral on Northern Oil & Gas, Lowers Price Target to $30

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) with a Neutral and lowers the price target from $6 to $5.25.

GDRX

UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $5.25

Piper Sandler analyst Mark Lear maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $35 to $30.

Piper Sandler Maintains Overweight on Murphy Oil, Lowers Price Target to $30

Piper Sandler analyst Mark Lear maintains Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) with a Neutral and lowers the price target from $25 to $24.

Piper Sandler Maintains Neutral on Magnolia Oil & Gas, Lowers Price Target to $24

VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) reported quarterly earnings of $54.74 per share. This is a 72.67 percent decrease over earnings of $200.28 per share from the same period last year. The company reported $27.82 million in sales this quarter. This is a 40.64 percent increase over sales of $19.79 million the same period last year.

Earnings

VCIG

VCI Global FY EPS $54.74 Down From $200.28 YoY, Sales $27.82M Up From $19.79M YoY

Piper Sandler analyst Mark Lear maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and lowers the price target from $234 to $225.

FANG

Piper Sandler Maintains Overweight on Diamondback Energy, Lowers Price Target to $225

NuScale Power Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares surged 21.4% to $21.60 on Tuesday following the <a href="https://www.benzinga.com/pressreleases/25/05/b45359929/nuscale-power-reports-first-quarter-2025-results">release</a> of its first-quarter earnings after Monday&#8217;s close.
What To Know: The company <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">reported</a> quarterly revenue of $13.4 million, significantly surpassing analysts&#8217; expectations of $4.26 million. The revenue boost was attributed to progress on its FEED Phase 2 project and a Technology License Agreement for Romania's RoPower Doicești power plant.
NuScale reduced its quarterly operating expenses by $2.3 million year-over-year to $42.3 million, largely due to lower R&amp;D costs as the company advances from development toward commercialization. The company&#8217;s net loss from operations narrowed to $35.3 million from $44.0 million in the same quarter last year.
Read Also: <a href="https://www.benzinga.com/news/25/05/45380609/applovin-stock-surges-on-strong-q1-earnings-and-tariff-truce-tailwinds">AppLovin Stock Surges On Strong Q1 Earnings And Tariff Truce Tailwinds</a>
CEO John Hopkins <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">emphasized</a> NuScale's ongoing momentum as the only SMR provider with US NRC design approval. He noted that 12 reactor modules are already in production, with a target delivery date set for 2030.
NuScale, along with partner ENTRA1 Energy, is in advanced discussions with a range of potential customers, including governments, data centers and energy firms. 
The company ended the quarter with $521.4 million in liquidity and raised $102.4 million through its ATM equity program, reinforcing its capital position as it scales operations.
Read Also: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>
<h2 class="wp-block-heading">How To Buy SMR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in NuScale Power&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SMR has a 52-week high of $32.30 and a 52-week low of $5.86.

NuScale (SMR) Stock Surges 21% After Smashing Q1 Revenue Estimates

TD Cowen analyst Joseph Thome initiates coverage on Bright Minds Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) with a Buy rating.

Initiation

DRUG

TD Cowen Initiates Coverage On Bright Minds Biosciences with Buy Rating

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and raises the price target from $35 to $48.

Piper Sandler Maintains Neutral on EQT, Raises Price Target to $48

Western Digital shares are trading higher after the company announced a $2 billion buyback program.

Piper Sandler analyst Mark Lear maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Overweight and lowers the price target from $56 to $53.

Piper Sandler Maintains Overweight on Devon Energy, Lowers Price Target to $53

HOOD

Robinhood shares are trading higher after the company announced a deal to acquire WonderFi.

ARRY

FSLR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Shares of solar stocks are trading higher on reports indicating the House GOP budget will cut but not remove wind and solar tax credits.

UBS analyst Chris Kuntarich maintains Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) with a Buy and raises the price target from $55 to $57.

UBS Maintains Buy on Life360, Raises Price Target to $57

Piper Sandler analyst Mark Lear maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and lowers the price target from $37 to $36.

CTRA

Piper Sandler Maintains Overweight on Coterra Energy, Lowers Price Target to $36

Small Cap

Press Releases

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

Comments

NeuroSense Therapeutics

空売り

NeuroSense Therapeutics (NASDAQ:NRSN) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル